Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.

被引：0
|
作者：
Suzuki, Maya [1 ]
Cheung, Irene Y. [1 ]
Cheung, Nai-Kong V. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10570
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Anti-GD2 immunotherapy for neuroblastoma
    Sait, Sameer
    Modak, Shakeel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (10) : 889 - 904
  • [2] Survival of Neuroblastoma Patients in Countries with Limited Access to ANTI-GD2 Immunotherapy
    Yu, U.
    Xu, H.
    Chen, S.
    Yi, M.
    Liu, C.
    Liu, S.
    Yuan, X.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S216 - S216
  • [3] Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma.
    Lode, Holger N.
    Schmidt, Manuela
    Seidel, Diana
    Huebener, Nicole
    Brackrock, Diana
    Bleeke, Matthias
    Reker, Daniel
    Brandt, Sven
    Mueller, Hans-Peter
    Helm, Christiane
    Siebert, Nikolai
    CANCER RESEARCH, 2013, 73
  • [4] Lineage plasticity dictates responsiveness to anti-GD2 therapy in neuroblastoma.
    Mabe, Nathaniel W.
    Huang, Min
    Schaefer, Daniel A.
    Dalton, Guillermo N.
    Digiovanni, Giulia
    Alexe, Gabriela
    Geraghty, Anna C.
    Khalid, Delan
    Mader, Marius M.
    Sheffer, Michal
    Linde, Miles H.
    Ly, Nghi
    Rotiroti, Maria Caterina
    Smith, Benjamin A. H.
    Wernig, Marius
    Bertozzi, Carolyn R.
    Monje, Michelle
    Mitsiades, Constantine
    Majeti, Ravindra
    Satpathy, Ansuman T.
    Stegmaier, Kimberly
    Majzner, Robbie G.
    CANCER RESEARCH, 2022, 82 (23) : 3 - 3
  • [5] Prolonged ILEUS Secondary to Anti-Gd2 Immunotherapy for Neuroblastoma
    Osuna Marco, M.
    Alcaide Alvarez, C.
    Barrio Merino, A.
    Cilla, C.
    Bengoechea, C.
    Lancharro, A.
    Villa Alcazar, M.
    Lopez-Ibor, B.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S524 - S524
  • [6] Outcome of Anti-GD2 Immunotherapy in Dutch Patients with High-Risk Neuroblastoma
    Tas, M.
    Dootjes, L.
    Fiocco, M.
    de Krijger, R.
    Dierselhuis, M.
    van Eijkelenburg, N.
    van Grotel, M.
    Kraal, K.
    Peek, A.
    van de Ven, K.
    de Keizer, B.
    Littooij, A.
    Janssens, G.
    Tytgat, G.
    van Noesel, M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S341 - S342
  • [7] Anti-GD2 antibody internalization by neuroblastoma as a mechanism of immunotherapy resistance
    Tibbetts, Rachelle J.
    Yeo, Kee Kiat
    Muthugounder, Sakunthala
    Asgharzadeh, Shahab
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
    Yu, Alice L.
    Gilman, Andrew L.
    Ozkaynak, M. Fevzi
    London, Wendy B.
    Kreissman, Susan G.
    Chen, Helen X.
    Smith, Malcolm
    Anderson, Barry
    Villablanca, Judith G.
    Matthay, Katherine K.
    Shimada, Hiro
    Grupp, Stephan A.
    Seeger, Robert
    Reynolds, C. Patrick
    Buxton, Allen
    Reisfeld, Ralph A.
    Gillies, Steven D.
    Cohn, Susan L.
    Maris, John M.
    Sondel, Paul M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14): : 1324 - 1334
  • [9] MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy
    Kushner, Brian H.
    LaQuaglia, Michael P.
    Modak, Shakeel
    Wolden, Suzanne L.
    Basu, Ellen M.
    Roberts, Stephen S.
    Kramer, Kim
    Yataghene, Karima
    Cheung, Irene Y.
    Cheung, Nai-Kong V.
    ONCOTARGET, 2017, 8 (56) : 95293 - 95302
  • [10] Correlation of anti-idiotype network with survival following anti-GD2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma
    Cheung, NKV
    Guo, HF
    Cheung, IY
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 35 (06): : 635 - 637
12345